Chronic administration of hexarelin attenuates cardiac fibrosis in the spontaneously hypertensive rat
Authors:
- 15 September 2012
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Heart and Circulatory Physiology
- Vol. 303 (6) , H703-H711
Abstract
Cardiac fibrosis is a hallmark of heart disease and plays a vital role in cardiac remodeling during heart diseases, including hypertensive heart disease. Hexarelin is one of a series of synthetic growth hormone secretagogues (GHSs) possessing a variety of cardiovascular effects via action on GHS receptors (GHS-Rs). However, the role of hexarelin in cardiac fibrosis in vivo has not yet been investigated. In the present study, spontaneously hypertensive rats (SHRs) were treated with hexarelin alone or in combination with a GHS-R antagonist for 5 wk from an age of 16 wk. Hexarelin treatment significantly reduced cardiac fibrosis in SHRs by decreasing interstitial and perivascular myocardial collagen deposition and myocardial hydroxyproline content and reducing mRNA and protein expression of collagen I and III in SHR hearts. Hexarelin treatment also increased matrix metalloproteinase (MMP)-2 and MMP-9 activities and decreased myocardial mRNA expression of tissue inhibitor of metalloproteinase (TIMP)-1 in SHRs. In addition, hexarelin treatment significantly attenuated left ventricular (LV) hypertrophy, LV diastolic dysfunction, and high blood pressure in SHRs. The effect of hexarelin on cardiac fibrosis, blood pressure, and cardiac function was mediated by its receptor, GHS-R, since a selective GHS-R antagonist abolished these effects and expression of GHS-Rs was upregulated by hexarelin treatment. In summary, our data demonstrate that hexarelin reduces cardiac fibrosis in SHRs, perhaps by decreasing collagen synthesis and accelerating collagen degradation via regulation of MMPs/TIMP. Hexarelin-reduced systolic blood pressure may also contribute to this reduced cardiac fibrosis in SHRs. The present findings provided novel insights and underscore the therapeutic potential of hexarelin as an antifibrotic agent for the treatment of cardiac fibrosis.Keywords
This publication has 43 references indexed in Scilit:
- Cardiac autonomic function in acutely nitric oxide deficient hypertensive rats: role of the sympathetic nervous system and oxidative stressCanadian Journal of Physiology and Pharmacology, 2011
- Chronic Losartan Administration Reduces Mortality and Preserves Cardiac but Not Skeletal Muscle Function in Dystrophic MicePLOS ONE, 2011
- Angiotensin-converting enzyme 2 activation protects against hypertension-induced cardiac fibrosis involving extracellular signal-regulated kinasesExperimental Physiology, 2011
- Temporal characteristics of cardiomyocyte hypertrophy in the spontaneously hypertensive ratCardiovascular Pathology, 2004
- Growth hormone-releasing peptide can improve left ventricular dysfunction and attenuate dilation in dilated cardiomyopathic hamstersCardiovascular Research, 2004
- CD36 Mediates the Cardiovascular Action of Growth Hormone-Releasing Peptides in the HeartCirculation Research, 2002
- Hypertrophic cardiomyopathy and sudden death in the young: Pathologic evidence of myocardial ischemiaHuman Pathology, 2000
- Tissue inhibitors of metalloproteinases: evolution, structure and functionBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 2000
- Regulation of cardiovascular collagen synthesis by mechanical loadCardiovascular Research, 1999
- Effect of chronic colchicine administration on the myocardium of the aging spontaneously hypertensive ratMolecular and Cellular Biochemistry, 1997